Free Trial
OTCMKTS:ALPMY

Astellas Pharma (ALPMY) Stock Price, News & Analysis

Astellas Pharma logo
$10.53 +0.06 (+0.55%)
As of 12:41 PM Eastern

About Astellas Pharma Stock (OTCMKTS:ALPMY)

Advanced

Key Stats

Today's Range
$10.34
$10.66
50-Day Range
$10.44
$11.71
52-Week Range
$8.37
$12.45
Volume
49,806 shs
Average Volume
173,852 shs
Market Capitalization
$19.05 billion
P/E Ratio
35.09
Dividend Yield
3.23%
Price Target
N/A
Consensus Rating
Buy

Company Overview

Receive ALPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ALPMY Stock News Headlines

Options Pro Reveals His #1 Retirement Income Trade
The current market is creating a perfect setup for my favorite trading strategy — one that doesn’t rely on risky crypto or waiting months for AI stocks to move. I’ve outlined exactly how it works in a free guide called How To Master The Retirement Trade, showing how I target short-term trades designed to deliver faster results with less stress.tc pixel
Astellas Announces Top Management Personnel Change
See More Headlines

ALPMY Stock Analysis - Frequently Asked Questions

Astellas Pharma's stock was trading at $9.66 on January 1st, 2025. Since then, ALPMY shares have increased by 7.5% and is now trading at $10.38.

Astellas Pharma Inc. (OTCMKTS:ALPMY) posted its quarterly earnings data on Wednesday, July, 30th. The company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.14 by $0.26. The company had revenue of $3.41 billion for the quarter, compared to analyst estimates of $3.20 billion. Astellas Pharma had a trailing twelve-month return on equity of 19.67% and a net margin of 4.34%.

Shares of Astellas Pharma split on Wednesday, April 2nd 2014.The 5-4 split was announced on Friday, March 14th 2014. The newly minted shares were issued to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split.

Astellas Pharma subsidiaries include these companies: Iota Biosciences, Nanna Therapeutics, Xyphos, Audentes Therapeutics, Potenza Therapeutics, Quethera, Universal Cells Inc., and more.

Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
7/30/2025
Today
10/16/2025
Next Earnings (Estimated)
10/29/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
N/A
Current Symbol
OTCMKTS:ALPMY
CIK
1446390
Fax
N/A
Employees
14,754
Year Founded
1923

Profitability

EPS (Trailing Twelve Months)
$0.30
Trailing P/E Ratio
34.90
Forward P/E Ratio
24.93
P/E Growth
N/A
Net Income
$334.93 million
Net Margins
4.34%
Pretax Margin
1.63%
Return on Equity
19.67%
Return on Assets
8.71%

Debt

Debt-to-Equity Ratio
0.38
Current Ratio
1.17
Quick Ratio
0.89

Sales & Book Value

Annual Sales
$12.56 billion
Price / Sales
1.51
Cash Flow
$1.81 per share
Price / Cash Flow
5.80
Book Value
$5.52 per share
Price / Book
1.90

Miscellaneous

Outstanding Shares
1,809,660,000
Free Float
N/A
Market Cap
$18.95 billion
Optionable
Not Optionable
Beta
0.25

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (OTCMKTS:ALPMY) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners